Ann: MSB Q2 Financial Results and Operational Highlights, page-28

I respectfully disagree that Silviu was referring to the existing grunenthal partnership agreement, which was modified last summer to allow Mesoblast to conduct a single additional trial with 20% paid by them (as they are providing the 20% patients from Europe according to the modified agreement).

Silviu said the new CLBP partner would mean MSB has to pay zero for the new trial. Let’s listen to the call again once it’s available to be heard as this is important.

Here is the original Grunenthal partnership announcement:
https://newsfilter.io/articles/grnenthal-and-mesoblast-enter-strategic-partnership-for-europe-and-latin-america-to-develop-and-comm-ec9fb116eb79f6760aad88f858158ab4